UK: NICE Approves Lung Perfusion Device for NHS Use
The Spin
Techno-optimist narrative
The XVIVO perfusion system is a game-changer for lung transplants in England and Wales. Right now, only 23% of donated lungs get used, and up to one in five adults on the urgent transplant list die before a suitable organ is found. NICE backing this technology means transplant centers can rescue up to nearly four in five currently discarded lungs, giving hundreds more patients a real shot at survival.
Techno-skeptic narrative
NICE's backing is conditional approval, not proof the device works. The clinical case rests mostly on small observational studies, not randomized trials. Even transplant physicians want proof it actually boosts transplants before hailing it — four years of data collection lie ahead. "Breakthrough" headlines are outrunning evidence NICE itself admits doesn't yet exist.
Establishment-critical narrative
Perfusion technology expands a system still arguing with itself over what counts as death. In some donation after circulatory death (DCD) cases, donors are declared dead after only a brief pause in circulation, then surgeons restart blood flow to organs while deliberately blocking it to the brain — a practice serious enough that the American College of Physicians has called for a pause until it's reconciled with the rule that donors must truly be dead first. Expanding organ-preservation technology deepens reliance on exactly this contested donor pool.